Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption

Basit Öğe Kaydı
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridYigenoglu, Tugce/0000-0001-9962-8882;
dc.authorwosidKorkmaz, Serdal/IST-3736-2023
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidYigenoglu, Tugce/ABF-6595-2021
dc.authorwosidUlas, Turgay TU/A-6050-2018
dc.contributor.authorYigenoglu, Tugce Nur
dc.contributor.authorUlas, Turgay
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorAltuntas, Fevzi
dc.date.accessioned2024-08-04T20:47:28Z
dc.date.available2024-08-04T20:47:28Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe activation of the innate and adaptive immune systems by SARS-CoV-2 causes the release of several inflammatory cytokines, including IL-6. The inflammatory hypercytokinemia causes immunopathological changes in the lungs including vascular leakage, and alveolar edema. As a result of these changes in the lungs, hypoxia and acute respiratory distress syndrome occur in patients with COVID-19. Even though there are clinical trials on the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVID-19. Pharmacological approaches have shown poor results in sepsis-like syndromes caused by the hypercytokinemia. Suppressing the cytokine storm is an important way to prevent the organ damage in patients with COVID-19. Extracorporeal blood purification could be proposed as an adjunctive therapy for sepsis, aiming to control the associated dysregulation of the immune system, which is known to protect organ functions. Several extracorporeal blood purification therapies are now available, and most of them target endotoxins and/or the cytokines and aim improving the immune response. For this purpose, plasmapheresis and immunoadsorption may be an important adjunctive treatment option to manage the complications caused by cytokine storm in critically ill patients with COVID-19.en_US
dc.identifier.doi10.1016/j.transci.2020.102855
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue4en_US
dc.identifier.pmid32636114en_US
dc.identifier.scopus2-s2.0-85087393966en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2020.102855
dc.identifier.urihttps://hdl.handle.net/11616/99389
dc.identifier.volume59en_US
dc.identifier.wosWOS:000564554400032en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBlood purification therapiesen_US
dc.subjectCOVID-19en_US
dc.subjectHypercytokinemiaen_US
dc.titleExtracorporeal blood purification treatment options for COVID-19: The role of immunoadsorptionen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu